Antitumor tests of amygdalin in transplantable animal tumor systems (1978)

Peer-Reviewed Study · C. Chester Stock, George S. Tarnowski, Franz A. Schmid, Dorris J. Hutchison, Morris N. Teller · 1978

C. Chester Stock et al., 1978: Companion paper testing amygdalin against ten transplantable mouse and rat tumours plus DMBA-induced mammary carcinoma; no antitumour effect in any system. Oral dosing at 500 mg/kg/day was lethal, with hydrogen cyanide detected in the cages.

Under the experimental conditions, AM exhibited no antitumor effects.

Results, unpaginated web record

C. Chester Stock et al., 1978: Companion paper testing amygdalin against ten transplantable mouse and rat tumours plus DMBA-induced mammary carcinoma; no antitumour effect in any system. Oral dosing at 500 mg/kg/day was lethal, with hydrogen cyanide detected in the cages. Drug sample: amygdalin MF prepared in Mexico for the McNaughton Foundation; FDA performed the analytical work. Comparator: untreated controls in each tumour system. Conflicts: none declared in retrieved text. Toxicity note relevant to C1: oral amygdalin killed mice at 500 mg/kg/day, consistent with the cyanide findings in patients (CHF-01). Study type: animal.